DIETY AP FEPROREX FENPROPROREX 20 MG 30 TABS EXTENDED RELEASE
DIETY AP 20MG FENPROPOREX 30 TABLETS
Diety AP 20mg is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. However, due to an addictive potential, it is listed as an illicit substance in many countries. Structurally, IFA Diety AP 20mg (N-2-cyanoethylamphetamine) falls within the phenylethamine and amphetamine chemical class of drugs.
IFA Diety AP 20mg is an amphetamine based anorectic which is rapidly metabolized into amphetamine in the body.
It is not recommended to stop using IFA DIETY AP 20MG (FENPROPOREX) abruptly, unless there are side effects. The doctor will guide the progressive reduction of the medication until its total interruption, which will be different in each patient.
IFA DIETY 20MG (FENPROPOREX) is also not recommended to consume beyond the dose recommended by the doctor. In the event of any side effect, you should immediately contact the doctor who prescribed Fenproporex, to consider interrupting or changing the dose.
It is indicated as an adjunct in the treatment of exogenous obesity, associated with a hypocaloric diet.
The fenproporex is a derivative of phenylisopropylamines acting on brain centers control -Ape -tito and specifically on the ascending reticular activating system, with drug levels within 30-60 minutes after ingestion, peaking at 2-4 hours with a duration of 6 to 8 hours.
The route of excretion is the kidney, much is excreted in the urine and the remainder excreted as metabolites with an average time of removal within 48 hours.
Diety AP is contraindicated in patients with severe arterial hypertension, ischemic heart disease, renal failure, glaucoma, advanced arteriosclerosis, and in patients hypersensitive to fenproporex or idiosyncrasy to sympathomimetic amines, states of agitation or emotionally unstable individuals who are susceptible or history of drug or alcohol abuse.
The association with non-selective MAOIs is contraindicated since this may trigger paroxysmal hypertension or malignant hyperthermia due to the prolonged action of MAOIs.
This interaction is possible even 15 days after stopping the administration of MAOIs. In pregnancy and lactation.
– Must not exceed the recommended dose, however, the drug should be discontinued when the patient stops losing weight.
– Must be used with a high degree of caution in severe arterial hypertension, ischemic heart disease, renal failure, glaucoma and advanced arteriosclerosis.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION
In the absence of experimental studies according to current regulations and increasing human clinical data, the risk is unknown, and consequently as a precautionary measure should not be prescribed fenproporex during pregnancy and lactation.
In some sensitive individuals may receive the following symptoms that may alter the normal behavior tachycardia, insomnia or excitation light, dry mouth, constipation.
DRUG INTERACTIONS AND OTHER GENDER
The fenproporex not be provided in partnership with other anorectics. Anorectics should not be associated with MAOIs.It is not advisable partnership with guanethidine and its derivatives, since this group of drugs produces abolition of the antihypertensive effect of guanethidine (guanethidine moving there from its neuronal site of action).
Avoid indirect sympathomimetic drugs or use other antihypertensive drugs.
Please consult your personal physician before taking any medication.
The initial dose is 10 mg / day. With lack of effectiveness when used in this dose (weight loss less than 2 kg for 4 weeks) and if tolerated the dose can be increased to 15 mg / day.
If no effect when Ifa Diety Getz Pharma used in doses of 15 mg / day (weight loss less than 2 kg per 4 weeks), this drug should be discontinued.
In patients not adequately responding to treatment, that is who within 3 months can not reach the level of 5% weight loss from baseline, the duration of use this medication should not exceed 3 months.
The course of treatment is not more than 1 year since no data on efficacy and safety of longer use.
Do not use sibutramine, if after made weight loss achieved in the course of further therapy, the patient again adds to the weight of 3 kg or more.
Digestive system: frequently – anorexia, constipation, dry mouth, nausea, transient increases in liver enzymes.
CNS and peripheral nervous system: insomnia, headaches, dizziness, anxiety, paresthesia, increased sweating, change in taste, seizures; one patient with schizoaffective disorder, which presumably existed prior to initiating therapy with sibutramine after treatment developed acute psychosis.
Cardiovascular system: tachycardia, palpitations, increased blood pressure (moderate rise of blood pressure at rest of 1-3 mm Hg and a moderate increase in heart rate by 3-7 beats / min), vasodilation (flushing with a sensation of heat), exacerbation of hemorrhoids; in some cases – a more pronounced increase in blood pressure and heart rate acceleration.
Urinary system: in rare cases – acute interstitial nephritis, mesangiocapillary glomerulonephritis.
Blood coagulation system: thrombocytopenia, Henoch-Schonlein purpura.Most often side effects occur early in therapy (the first 4 weeks), their severity and frequency of occurrence over time are weaken.